<DOC>
	<DOC>NCT01485822</DOC>
	<brief_summary>The purpose of this study was to assess the pigmentation in the trabecular meshwork of patients who had been treated for at least 2 years with TRAVATAN compared with patients without exposure (or less than 1 month) to a prostaglandin analogue (PGA).</brief_summary>
	<brief_title>A Multicenter Study of the Pigmentation in the Trabecular Meshwork After Two Years of Treatment With TRAVATAN 0.004% Ophthalmic Solution</brief_title>
	<detailed_description />
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma, Open-Angle</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Travoprost</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Diagnosis of openangle glaucoma without pseudoexfoliation or pigment dispersion component; Either two or more years of dosing with Travatan, or no prior exposure (less than 1 month) to a topical ocular prostaglandin; Requires a trabeculectomy; Other protocoldefined inclusion criteria may apply. Pseudoexfoliation or pigment dispersion; History of chronic or recurrent severe inflammatory eye disease; History of or current ocular infection or ocular inflammation within the past 3 months in either eye; Greater than one month but less than two years of exposure to TRAVATAN; Pregnant, breastfeeding, not using highly effective birth control; Other protocoldefined exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Glaucoma</keyword>
	<keyword>Travatan</keyword>
	<keyword>Trabeculectomy</keyword>
</DOC>